Spread of Zika virus disease

Keyword(s):  
2016 ◽  
Vol 65 (12) ◽  
Author(s):  
Naomi K. Tepper ◽  
Howard I. Goldberg ◽  
Manuel I. Vargas Bernal ◽  
Brenda Rivera ◽  
Meghan T. Frey ◽  
...  

2021 ◽  
Vol 83 (4) ◽  
Author(s):  
Mahmoud A. Ibrahim ◽  
Attila Dénes

AbstractWe present a compartmental population model for the spread of Zika virus disease including sexual and vectorial transmission as well as asymptomatic carriers. We apply a non-autonomous model with time-dependent mosquito birth, death and biting rates to integrate the impact of the periodicity of weather on the spread of Zika. We define the basic reproduction number $${\mathscr {R}}_{0}$$ R 0 as the spectral radius of a linear integral operator and show that the global dynamics is determined by this threshold parameter: If $${\mathscr {R}}_0 < 1,$$ R 0 < 1 , then the disease-free periodic solution is globally asymptotically stable, while if $${\mathscr {R}}_0 > 1,$$ R 0 > 1 , then the disease persists. We show numerical examples to study what kind of parameter changes might lead to a periodic recurrence of Zika.


KYAMC Journal ◽  
2017 ◽  
Vol 7 (1) ◽  
pp. 719-725
Author(s):  
Md Daharul Islam ◽  
SM Tajdit Rahman ◽  
Khaleda Akhter ◽  
Md Azizul Hoque ◽  
Anannya Roy ◽  
...  

Zika virus is a flavivirus related to Dengue virus, yellow fever virus and West Nile virus. It is considered an emerging arbovirus transmitted by mosquito of the genus Aedes. Its first description took place in 1947 in the Zika Forest in Uganda, isolated on Rhesus monkey used as bait to study the yellow fever virus. Clinical picture is characterized as a 'dengue-like' syndrome, with abrupt onset of fever; and an early onset of evanescent rash, often pruritic. Occasionally the disease has been associated with Guillain-Barré syndrome. The diagnosis can be performed by PCR or by IgG and IgM antibodies detection. No specific treatment or vaccine is available for Zika virus disease. Treatment is generally supportive. Control measures are same for dengue and chikungunya based mostly on health education and vector control.KYAMC Journal Vol. 7, No.-1, Jul 2016, Page 719-725


2021 ◽  
Vol 49 (1) ◽  
Author(s):  
Mainak Bardhan ◽  
Debolina Pramanik ◽  
Rizana Riyaz ◽  
Mohammad Mehedi Hasan ◽  
Mohammad Yasir Essar

AbstractThe COVID-19 pandemic has wreaked havoc in the world from last year, and any further insults like Zika virus will surely bring the apocalypse unto us. In July 2021, Zika began spreading in India, mainly in the state of Kerala. Zika infection resembles closely COVID-19 and other arboviral infections, which might lead to delayed and misdiagnosis, further leading to underreporting of cases. Some of the feared complications of Zika include Guillain–Barré syndrome and congenital Zika syndrome leading to microcephaly. Thus, Zika virus disease (ZVD) has significant public health and social impacts. Since the trifecta of infectious diseases (host, agent and environment) are all conducive to the spread of Zika in India, there is a huge risk that ZVD might become endemic in India, which is especially dangerous in the backdrop of this pandemic. This has to be stopped at all costs: the main aspects of which are public health measures, vector control and early diagnosis, especially in case of pregnant women. The diversion of healthcare resources for this pandemic has albeit made this difficult, but we must do our bit if we have to overcome this situation.


2017 ◽  
Vol 5 (1) ◽  
pp. 2
Author(s):  
AdelI Al-Afaleq
Keyword(s):  

2021 ◽  
Vol 12 ◽  
Author(s):  
Amelia K. Pinto ◽  
Mariah Hassert ◽  
Xiaobing Han ◽  
Douglas Barker ◽  
Trevor Carnelley ◽  
...  

The closely related flaviviruses, dengue and Zika, cause significant human disease throughout the world. While cross-reactive antibodies have been demonstrated to have the capacity to potentiate disease or mediate protection during flavivirus infection, the mechanisms responsible for this dichotomy are still poorly understood. To understand how the human polyclonal antibody response can protect against, and potentiate the disease in the context of dengue and Zika virus infection we used intravenous hyperimmunoglobulin (IVIG) preparations in a mouse model of the disease. Three IVIGs (ZIKV-IG, Control-Ig and Gamunex®) were evaluated for their ability to neutralize and/or enhance Zika, dengue 2 and 3 viruses in vitro. The balance between virus neutralization and enhancement provided by the in vitro neutralization data was used to predict the IVIG concentrations which could protect or enhance Zika, and dengue 2 disease in vivo. Using this approach, we were able to define the unique in vivo dynamics of complex polyclonal antibodies, allowing for both enhancement and protection from flavivirus infection. Our results provide a novel understanding of how polyclonal antibodies interact with viruses with implications for the use of polyclonal antibody therapeutics and the development and evaluation of the next generation flavivirus vaccines.


2017 ◽  
Vol 7 (12) ◽  
pp. 809-810
Author(s):  
Somsri Wiwanitkit ◽  
◽  
Viroj Wiwanitkit ◽  
◽  
◽  
...  

2019 ◽  
Vol 24 (45) ◽  
Author(s):  
Sandra Giron ◽  
Florian Franke ◽  
Anne Decoppet ◽  
Bernard Cadiou ◽  
Thierry Travaglini ◽  
...  

On 1 October 2019, a locally-acquired Zika virus disease case was laboratory confirmed in Hyères, Var department. Active case finding identified two additional locally-acquired cases living within 90 m, with symptom onset 8 days before the index case. Extensive patient interviews did not yield information supporting transmission through sexual contact or substances of human origin. Vector-borne transmission by local Aedes albopictus mosquitoes is the most likely mode of transmission. Here we describe the public health response.


Sign in / Sign up

Export Citation Format

Share Document